Author Interviews, COVID -19 Coronavirus, Infections / 09.07.2020
New Heated Filter Can ‘Catch and Kill’ COVID-19 Virus
MedicalResearch.com Interview with:
[caption id="attachment_54818" align="alignleft" width="142"]
Dr. Ren[/caption]
Zhifeng Ren PhD
M. D. Anderson Chair Professor
Department of Physics Director
Texas Center for Superconductivity at UH
University of Houston
Texas 77204
MedicalResearch.com: What is the background for this study?
Response: COVID-19 pandemic has been spreading in the whole world in the past a few months, has infected more than 12 million and killed more than 0.5 million people.
We have to find an effective way to catch and kill the SARS-CoV-2 viruses to stop the spread before the vaccine is ready.
Dr. Ren[/caption]
Zhifeng Ren PhD
M. D. Anderson Chair Professor
Department of Physics Director
Texas Center for Superconductivity at UH
University of Houston
Texas 77204
MedicalResearch.com: What is the background for this study?
Response: COVID-19 pandemic has been spreading in the whole world in the past a few months, has infected more than 12 million and killed more than 0.5 million people.
We have to find an effective way to catch and kill the SARS-CoV-2 viruses to stop the spread before the vaccine is ready.
Samia Arshad[/caption]
Samia Arshad, MPH
Epidemiologist II
Infectious Disease
Henry Ford Hospital, Detroit, MI
I would like to start off by saying: We need to keep partisanship out of science. During this pandemic, we hope we can stick to science and help save lives with purposeful data driven facts.
MedicalResearch.com: What is the background for this study?
Response: Hydroxychloroquine, an antimalarial and immunomodulatory agent has demonstrated antiviral activity against SARS-CoV-2. We are in an acceleration phase of the COVID-19 pandemic, with 25% of the world’s cases occurring in the United States. Currently there is no known therapy or vaccine for treatment of SARS-CoV-2, highlighting the urgency around identifying effective therapies. The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.
Dr. Blume[/caption]
Dr. Christine Blume PhD
Centre for Chronobiology
Psychiatric Hospital of the University of Basel
Transfaculty Research Platform Molecular and Cognitive Neurosciences
Basel
MedicalResearch.com: What is the background for this study?
Response: In modern societies, human rest-activity rhythms and sleep are between the often-conflicting poles of external social time (e.g., work hours and leisure activities) and an individual’s internal biological time. This can lead to so-called “social jetlag”, which has repeatedly been associated with detrimental health effects. With the restrictions to control the pandemic, social timing relaxed as people many started working from home and public life came to a standstill. In an online survey with 435 respondents, we investigated the effects of the phase with the strictest COVID-19 restrictions on the relationship between social and biological rhythms as well as sleep during a six-week period (mid-March until end of April 2020) in three European societies (Austria, Germany, Switzerland).
Dr. Hooker[/caption]
Edmond A. Hooker, MD, DrPH
Professor, Department of Health Services Administration
MHSA Associate Director for Accreditation
Xavier University
Cincinnati, Ohio
MedicalResearch.com: What is the background for this study?
Response: Healthcare acquired infections are still a huge problem in the US. Most hospitals are not following the hospital bed manufacturers guidelines for cleaning these mattresses and bed decks (the metal bed frame). Many use only a single step, when the manufacturers recommend a 5-6 step process (pre-clean any obvious soil, clean, rinse off cleaner, disinfect, rinse off disinfectant, inspect mattress for damage). The problem is that, if done, this takes 45 minutes to 1 hours. Most hospitals turn over a hospital room in less than 30 minutes. The launderable bed cover allows the bed to be cleaned and turned over in minutes, not an hours.
Dr. Schünemann[/caption]
Holger Schünemann, MD, PhD, FRCPC
Professor of Clinical Epidemiology and of Medicine
Co-Director, WHO Collaborating Centre for Infectious Diseases,
Research Methods and Recommendations
Director, Cochrane Canada and McMaster GRADE Centre
Department of Health Research Methods, Evidence, and Impact
Canada
MedicalResearch.com: What is the background for this study?
Response: Many countries and regions have issued conflicting advice about physical distancing to reduce transmission of COVID-19, based on limited information. In addition, the questions of whether masks and eye coverings might reduce transmission of COVID-19 in the general population, and what the optimum use of masks in healthcare settings is, have been debated during the pandemic.
Dr. Alladina[/caption]
Jehan Alladina MD
Massachusetts General Hospital
Pulmonary and Critical Care Medicine
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: During the pandemic, clinicians around the world have shared anecdotal experiences to help inform care of patients with COVID-19. However, these anecdotes and observations, without careful analysis, can bias clinicians; many clinicians have even recommended experimental therapies based on this information alone.
To that end, the goal of our study was to rigorously examine the respiratory failure experienced by critically ill patients with COVID-19 and understand their response to the standards of care for respiratory failure.
Prof. Dagna[/caption]
Prof. Lorenzo Dagna MD FACP
Ospedale San Raffaele and
Vita-Salute San Raffaele University
Milan, Italy
MedicalResearch.com: What is the background for this study?
Response: Upon encountering pathogens, our immune system produces pro-inflammatory mediators, called cytokines. Cytokines activate cells from the immune system. In most people, production of cytokines is an appropriate and protective response to infection. However, some individuals develop excessive and detrimental inflammatory responses, which are even more harmful than the pathogen itself to the host organism.
We hypothesized that some patients with COVID-19 might develop excessive and detrimental inflammation, and that treatment with anti-inflammatory agents might be beneficial in this population.
Anakinra is an inhibitor of the pro-inflammatory molecule interleukin 1 (IL-1). It was originally marketed for the treatment of rheumatoid arthritis, but is now mostly used to treat a variety of pediatric inflammatory diseases.
